Form 4: Rapport Therapeutics CSO Sells 8,500 Shares

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock on January 15, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), sold a total of 8,500 shares of common stock.
• The sales occurred on January 15, 2026.
• 8,300 shares were sold at a weighted average price of $26.8255 per share, with prices ranging from $26.33 to $27.30.
• An additional 200 shares were sold at a price of $27.4 per share.
• These transactions were executed under a Rule 10b5-1 trading plan established on December 12, 2024.
• Following these transactions, David Bredt beneficially owns 395,575 shares of common stock.

Sentiment

Score: 5

Explanation: The sale of shares by a Chief Scientific Officer is generally a neutral to slightly negative signal. However, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates much of the potential negative interpretation, as it suggests a planned liquidity event rather than a reaction to new, undisclosed negative information.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than an immediate reaction to new information.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Risks

• Potential negative market perception due to insider selling, which could lead to short-term share price volatility.

Future Outlook

NA

Management Comments

• These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

Industry Context

This filing is specific to an individual insider transaction and does not provide broader industry context or trends. Insider trading activity is a common data point for investors to assess management's confidence in the company's future, but a 10b5-1 plan mitigates the immediate signaling effect.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially leading to short-term sentiment shifts, though the 10b5-1 plan reduces the severity of this interpretation.

Key Dates

Recommendation

While insider selling can sometimes be a bearish signal, the execution of these sales under a pre-established 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new, adverse company developments. Investors should monitor future company performance and broader market conditions, but this specific filing does not present a strong case for a 'buy' or 'sell' recommendation based solely on this insider transaction.

Keywords

Rapport Therapeutics, RAPP, Insider Trading, Form 4, Stock Sale, David Bredt, Chief Scientific Officer, 10b5-1 Plan, Equity Transaction